EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations

Federica Di Vincenzo iD, Jacopo Iaccarino, Giuseppe Privitera iD, Cristina Bezzio, Lucrezia Laterza iD, Franco Scaldaferri, Alessandro Armuzzi

Expert Review of Clinical Pharmacology · 15.11.2026 · 1-18

DOI: 10.1080/17512433.2026.2763168 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 15.11.2026. Verfasst von Federica Di Vincenzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit - Centro di Malattie dell'Apparato Digerente (CeMAD), UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gem…. Die Arbeit nennt 112 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Crohn's disease (CD) remains a major clinical challenge, since many patients fail biologics or lose response. Selective IL-23p19 blockade is mechanistically attractive, targeting the IL-23/Th17 axis while preserving IL-12-dependent host defense. Risankizumab, the first selective IL-23p19 inhibitor approved for CD, is increasingly used in advanced therapy-experienced patients. AREAS COVERED: This narrative review summarizes risankizumab pharmacology, pivotal trial data, real-world effectiveness and safety in moderate-to-severe CD, emphasizing biologic-experienced and multiply exposed populations, based on PubMed, Scopus and Google Scholar searches (from inception to October 2026). It also examines difficult-to-treat phenotypes (postoperative recurrence, CD of the pouch, perianal, fistulising and stricturing disease, extraintestinal manifestations) and compares risankizumab with other IL-23p19 inhibitors. Positioning is discussed in light of the SEQUENCE trial and 2025 ACG and AGA guidelines, together with unresolved issues: special populations, predictive biomarkers and investigational combination therapy. EXPERT OPINION: Risankizumab is not a universal solution for refractory CD, but it is one of the best-supported options after anti-TNF failure, particularly for endoscopic outcomes. Evidence in multiply exposed patients and difficult-to-treat phenotypes is largely observational, and superiority over anti-TNF agents as first-line therapy is unproven. Major gaps persist in fistulising disease, special populations, head-to-head comparisons, predictive biomarkers, and sequencing or combination strategies.

Schlagwörter

Stichwörter der Autor:innen

Anti-IL-23p19Crohn’s diseaseeffectivenessinflammatory bowel diseasesrefractory diseaserisankizumabsafetysequencing

Autor:innen und Institutionen

  • IBD Unit - Centro di Malattie dell'Apparato Digerente (CeMAD), UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy.
  • IBD Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

ORCID-Profile: Federica Di Vincenzo, Giuseppe Privitera, Lucrezia Laterza

Zitieren

APA

Di Vincenzo, F., Iaccarino, J., Privitera, G., Bezzio, C., Laterza, L., Scaldaferri, F., & Armuzzi, A. (2026). Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations. Expert Review of Clinical Pharmacology, 1-18. https://doi.org/10.1080/17512433.2026.2763168

Vancouver

Di Vincenzo F, Iaccarino J, Privitera G, Bezzio C, Laterza L, Scaldaferri F, et al. Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations. Expert Review of Clinical Pharmacology. 2026:1-18. doi:10.1080/17512433.2026.2763168

BibTeX
@article{DiVincenzo2026,
  author = {Di Vincenzo, Federica and Iaccarino, Jacopo and Privitera, Giuseppe and Bezzio, Cristina and Laterza, Lucrezia and Scaldaferri, Franco and Armuzzi, Alessandro},
  title = {Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  pages = {1--18},
  doi = {10.1080/17512433.2026.2763168}
}
Kostenlos starten →